Ani Pharmaceuticals Inc (ANIP)

$61.35

-1.63

(-2.59%)

Market is closed - opens 7 PM, 19 Jul 2024

Performance

  • $61.02
    $63.03
    $61.35
    downward going graph

    0.54%

    Downside

    Day's Volatility :3.18%

    Upside

    2.66%

    downward going graph
  • $48.20
    $70.50
    $61.35
    downward going graph

    21.43%

    Downside

    52 Weeks Volatility :31.63%

    Upside

    12.98%

    downward going graph

Returns

PeriodAni Pharmaceuticals IncSector (Health Care)Index (Russel 2000)
3 Months
-2.48%
8.7%
0.0%
6 Months
13.29%
8.0%
0.0%
1 Year
21.37%
14.0%
0.0%
3 Years
92.66%
17.0%
-18.2%

Highlights

Market Capitalization
1.3B
Book Value
$23.26
Earnings Per Share (EPS)
1.61
PE Ratio
39.12
PEG Ratio
1.06
Wall Street Target Price
83.0
Profit Margin
6.87%
Operating Margin TTM
10.96%
Return On Assets TTM
3.91%
Return On Equity TTM
8.71%
Revenue TTM
517.5M
Revenue Per Share TTM
27.71
Quarterly Revenue Growth YOY
28.7%
Gross Profit TTM
177.6M
EBITDA
112.4M
Diluted Eps TTM
1.61
Quarterly Earnings Growth YOY
13.82
EPS Estimate Current Year
4.5
EPS Estimate Next Year
5.22
EPS Estimate Current Quarter
1.0
EPS Estimate Next Quarter
1.08

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Ani Pharmaceuticals Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
9
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 35.29%

Current $61.35
Target $83.00

Company Financials

FY18Y/Y Change
Revenue
201.6M
↑ 13.99%
Net Income
15.5M
↓ 1539.96%
Net Profit Margin
7.69%
↑ 8.3%
FY19Y/Y Change
Revenue
206.5M
↑ 2.47%
Net Income
6.1M
↓ 60.67%
Net Profit Margin
2.95%
↓ 4.74%
FY20Y/Y Change
Revenue
208.5M
↑ 0.93%
Net Income
-22.5M
↓ 470.0%
Net Profit Margin
-10.82%
↓ 13.77%
FY21Y/Y Change
Revenue
216.1M
↑ 3.67%
Net Income
-42.6M
↑ 88.94%
Net Profit Margin
-19.71%
↓ 8.89%
FY22Y/Y Change
Revenue
316.4M
↑ 46.38%
Net Income
-47.9M
↑ 12.42%
Net Profit Margin
-15.14%
↑ 4.57%
FY23Y/Y Change
Revenue
486.8M
↑ 53.87%
Net Income
18.8M
↓ 139.21%
Net Profit Margin
3.86%
↑ 19.0%
Q4 FY22Q/Q Change
Revenue
94.2M
↑ 12.42%
Net Income
-4.2M
↓ 50.66%
Net Profit Margin
-4.5%
↑ 5.76%
Q1 FY23Q/Q Change
Revenue
106.8M
↑ 13.32%
Net Income
1.4M
↓ 133.91%
Net Profit Margin
1.35%
↑ 5.85%
Q2 FY23Q/Q Change
Revenue
116.5M
↑ 9.14%
Net Income
6.2M
↑ 333.98%
Net Profit Margin
5.36%
↑ 4.01%
Q3 FY23Q/Q Change
Revenue
131.8M
↑ 13.11%
Net Income
9.9M
↑ 59.17%
Net Profit Margin
7.54%
↑ 2.18%
Q4 FY23Q/Q Change
Revenue
131.7M
↓ 0.13%
Net Income
1.2M
↓ 88.38%
Net Profit Margin
0.88%
↓ 6.66%
Q1 FY24Q/Q Change
Revenue
137.4M
↑ 4.39%
Net Income
18.2M
↑ 1476.36%
Net Profit Margin
13.25%
↑ 12.37%
FY18Y/Y Change
Total Assets
430.6M
↑ 4.48%
Total Liabilities
233.3M
↓ 1.7%
FY19Y/Y Change
Total Assets
456.8M
↑ 6.08%
Total Liabilities
244.0M
↑ 4.57%
FY20Y/Y Change
Total Assets
461.2M
↑ 0.96%
Total Liabilities
265.5M
↑ 8.81%
FY21Y/Y Change
Total Assets
771.6M
↑ 67.31%
Total Liabilities
412.9M
↑ 55.51%
FY22Y/Y Change
Total Assets
760.1M
↓ 1.49%
Total Liabilities
421.5M
↑ 2.1%
FY23Y/Y Change
Total Assets
904.4M
↑ 18.99%
Total Liabilities
471.7M
↑ 11.89%
Q4 FY22Q/Q Change
Total Assets
760.1M
↑ 2.84%
Total Liabilities
421.5M
↑ 4.75%
Q1 FY23Q/Q Change
Total Assets
765.2M
↑ 0.68%
Total Liabilities
425.7M
↑ 1.0%
Q2 FY23Q/Q Change
Total Assets
859.3M
↑ 12.3%
Total Liabilities
424.9M
↓ 0.21%
Q3 FY23Q/Q Change
Total Assets
889.9M
↑ 3.56%
Total Liabilities
435.2M
↑ 2.43%
Q4 FY23Q/Q Change
Total Assets
904.4M
↑ 1.63%
Total Liabilities
471.7M
↑ 8.38%
Q1 FY24Q/Q Change
Total Assets
914.5M
↑ 1.12%
Total Liabilities
462.6M
↓ 1.93%
FY18Y/Y Change
Operating Cash Flow
67.1M
↑ 70.16%
Investing Cash Flow
-27.4M
↓ 74.65%
Financing Cash Flow
-27.8M
↓ 138.44%
FY19Y/Y Change
Operating Cash Flow
45.6M
↓ 31.97%
Investing Cash Flow
-27.5M
↑ 0.62%
Financing Cash Flow
1.3M
↓ 104.49%
FY20Y/Y Change
Operating Cash Flow
15.3M
↓ 66.54%
Investing Cash Flow
-68.3M
↑ 148.0%
Financing Cash Flow
-1.4M
↓ 215.12%
FY21Y/Y Change
Operating Cash Flow
3.3M
↓ 78.24%
Investing Cash Flow
-105.5M
↑ 54.39%
Financing Cash Flow
194.6M
↓ 13622.93%
FY22Y/Y Change
Operating Cash Flow
-31.2M
↓ 1039.28%
Investing Cash Flow
-15.7M
↓ 85.08%
Financing Cash Flow
-5.1M
↓ 102.63%
Q4 FY22Q/Q Change
Operating Cash Flow
-4.4M
↓ 221.45%
Investing Cash Flow
-3.1M
↓ 67.98%
Financing Cash Flow
-508.0K
↓ 44.24%
Q1 FY23Q/Q Change
Operating Cash Flow
21.4M
↓ 586.91%
Investing Cash Flow
-2.4M
↓ 25.11%
Financing Cash Flow
-4.5M
↑ 795.28%
Q2 FY23Q/Q Change
Operating Cash Flow
20.6M
↓ 3.72%
Investing Cash Flow
-6.8M
↑ 190.1%
Financing Cash Flow
80.2M
↓ 1862.31%

Technicals Summary

Sell

Neutral

Buy

Ani Pharmaceuticals Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc
3.69%
13.29%
21.37%
92.66%
-22.25%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
10.54%
5.78%
48.82%
54.29%
63.43%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
5.44%
6.7%
6.06%
20.38%
20.38%
Zoetis Inc.
Zoetis Inc.
7.3%
-4.44%
6.41%
-7.98%
58.39%
Viatris Inc.
Viatris Inc.
17.81%
5.06%
16.31%
-12.94%
-27.54%
Catalent, Inc.
Catalent, Inc.
5.5%
19.25%
26.88%
-47.58%
7.02%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc
39.12
39.12
1.06
4.5
0.09
0.04
NA
23.26
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
39.96
39.96
0.44
3.98
0.18
0.1
NA
23.72
Haleon Plc Spon Ads
Haleon Plc Spon Ads
29.17
29.17
1.69
0.39
0.07
0.04
0.02
1.8
Zoetis Inc.
Zoetis Inc.
35.24
35.24
2.58
5.77
0.5
0.14
0.01
11.07
Viatris Inc.
Viatris Inc.
224.4
NA
0.06
2.73
0.0
0.03
0.04
16.81
Catalent, Inc.
Catalent, Inc.
211.02
NA
2.06
0.2
-0.28
-0.01
NA
19.96
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Ani Pharmaceuticals Inc
Ani Pharmaceuticals Inc
Buy
$1.3B
-22.25%
39.12
6.87%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$14.8B
63.43%
39.96
18.65%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$40.0B
20.38%
29.17
9.64%
Zoetis Inc.
Zoetis Inc.
Buy
$83.5B
58.39%
35.24
27.38%
Viatris Inc.
Viatris Inc.
Hold
$14.1B
-27.54%
224.4
-0.37%
Catalent, Inc.
Catalent, Inc.
Hold
$10.5B
7.02%
211.02
-28.44%

Insights on Ani Pharmaceuticals Inc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 131.65M → 137.43M (in $), with an average increase of 4.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 1.15M → 18.20M (in $), with an average increase of 93.7% per quarter

  • Vs NBIX

    In the last 1 year, Neurocrine Biosciences Inc. has given 48.8% return, outperforming this stock by 27.4%

Institutional Holdings

  • BlackRock Inc

    12.08%
  • Vanguard Group Inc

    6.23%
  • Rubric Capital Management LP

    4.57%
  • Deep Track Capital, LP

    3.92%
  • Dimensional Fund Advisors, Inc.

    2.91%
  • State Street Corporation

    2.74%

Company Information

ani pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. we focus on niche and high barrier to entry opportunities including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations. our two pharmaceutical manufacturing facilities located in baudette, minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize cortrophin gel and cortrophin-zinc.

Organization
Ani Pharmaceuticals Inc
Employees
642
CEO
Mr. Nikhil Lalwani
Industry
Health Technology

FAQs